激动素对大鼠肝纤维化后TGF—β1和CTGF变化的影响

目的 检测激动素（kinetin）对大鼠肝纤维化后转化生长因子β1（transforming growthfactor-β1，TGF-β1）和结缔组织生长因子（connective tissue growth factor，CTGF）含量变化的影响。方法将大鼠随机分为3组，模型组，用CCl4诱导形成肝纤维化模型；激动素组，CCl4造模同时给予0．1％激动素溶液0．5ml／100g／d（每天每100克体重大鼠注射0．5ml0．1％激动素溶液）皮下注射；对照组，给予生理盐水皮下注射，治疗12周。应用免疫组化和图像分析技术对3组中TGF-β1和CTGF含量及分布特点进行观察。结果激动素组TGF-β1为（1．339±0．244）％较模型组（1．904±0．367）％显著降低（P〈0．01），CTGF为（2．689±0．534）％较模型组（4．242±1．612）％显著降低（P〈0．01），上述两组TGF-β1和CTGF含量较正常对照组（0．926±0．277）％和（1．608±0．644）％显著升高（P〈0．01）。结论 激动素对实验性大鼠肝纤维化具有抑制作用。

EFFECT OF KINETIN ON THE ALTERATION OF TGF-a1 AND CTGF IN CCI4-INDUCED RAT HEPATIC FIBROSIS

Objective To detect the effect of kinetin on the alteration of TGF-β1 and CTGF in CCl4 induced rat hepatic fibrosis after kinetin treatment. Methods The rats were divided into three groups： （1）model group, liver fibrosis was induced in rats by subcutaneous injection of CCl4 ; （2） kinetin group, at the time of making model, 0. 1% kinetin solution of 0. 5ml/100g/d was injected subcutaneously; （3） control group, subcutaneous injection of normal saline lasted 12 weeks. The content and distribution of TGF- β1 and CTGF were observed with immunohistochemistry and image. Results The level of TGF-β1 in the kinetin treatment group was 1. 339± 0. 244%, significantly lower than that in the model group 1. 904± 0. 367% （P〈0.01）, and the level of CTGF in the treatment group was 2. 689±0. 534%, also significantly lower than that in the model group 4. 242±1. 612% （P〈0. 01） . The TGF-β1 and CTGF levels of the two groups were significantly higher than those in the control group 0. 926±0. 277% and 1.608±0. 644% （P〈0. 01） Conclusion Kinetin may have an inhibiting effect on CCl4-induced hepatic fibrosis in rats.